These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27263269)

  • 1. [Regulatory Framework for Approval of PET Drug in Korea: A Survey Report].
    Kurihara C; Inoue T
    Kaku Igaku; 2015 Nov; 52(4):341-52. PubMed ID: 27263269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Requirements for PET Drug Production.
    Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM
    J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European regulations for the introduction of novel radiopharmaceuticals in the clinical setting.
    Decristoforo C; Penuelas I; Patt M; Todde S
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):135-144. PubMed ID: 28124548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Instrumentation and radiopharmaceutical validation.
    Zigler SS
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years.
    Um SI; Sohn UD; Jung SY; You SH; Kim C; Lee S; Lee H
    Health Res Policy Syst; 2022 Jan; 20(1):4. PubMed ID: 34991612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
    Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
    Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
    Vallabhajosula S; Solnes L; Vallabhajosula B
    Semin Nucl Med; 2011 Jul; 41(4):246-64. PubMed ID: 21624560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
    Choi H; Lee H; Park B; Kim C; Lee J
    Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations.
    Bunning S; Ignace C; Mattmuller S; Schwarz SW; Scott PJH; VanBrocklin HF; Zigler SS;
    J Nucl Med; 2022 Jul; 63(7):1117-1123. PubMed ID: 35058318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Federal regulations and reimbursement for PET.
    Keppler JS
    J Nucl Med Technol; 2001 Dec; 29(4):173-9; quiz 180-2. PubMed ID: 11756528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.
    Zhu S; Mosessian S; Kroeger K; Sadeghi S; Slavik R; Kinloch S; Moore M; Allen-Auerbach M; Czernin J; Phelps M
    Mol Imaging Biol; 2020 Apr; 22(2):256-264. PubMed ID: 31240531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the compounding of positron emission tomography drugs.
    Hung JC
    Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.